ArticlePloS one2026
Application of symptom network analysis among patients with gastric cancer: A scoping review.
Article in PloS one, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo map evidence on symptom network analysis in patients with gastric cancer by summarizing study characteristics, commonly used assessment tools, central and bridge symptoms, temporal symptom relationships, and associated factors, and to provide a basis for precision symptom management.
methodsThis scoping review was guided by the Arksey and O'Malley framework and reported in accordance with the PRISMA extension for Scoping Reviews (PRISMA-ScR). PubMed, Web of Science, CINAHL, Cochrane Library, Embase, CNKI, Wanfang Data, VIP, and CBM were systematically searched from database inception to April 1, 2026. Original studies published in Chinese or English that applied symptom network analysis to gastric cancer populations, including eligible mixed cancer populations with gastric cancer patients, during the perioperative period or chemotherapy were included. Literature screening, data extraction, and narrative synthesis were performed.
resultsA total of 9 studies were included. Six symptom assessment tools were identified, with the Chinese version of the MD Anderson Symptom Inventory-Gastrointestinal Cancer Module (MDASI-GI-C) being the most frequently used tool (reported in 7 studies). Nine core symptoms were identified across the included studies, with fatigue being the most frequently reported core symptom (identified in 5 studies). Ten bridge symptoms were identified; however, considerable variation was observed in the identification of bridge symptoms across studies. Longitudinal analyses suggested that phlegm-dampness constitution was associated with subsequent changes in taste, while changes in taste were associated with subsequent appetite loss.
conclusionsThe symptom profiles of patients with gastric cancer are characterized by complexity, dynamic changes across treatment stages, and population heterogeneity. Symptom management strategies may benefit from individualized and stage-specific approaches targeting core symptoms, bridge symptoms, and key symptom pathways. Future research should focus on standardizing symptom assessment tools and assessment time points, conducting multicenter longitudinal studies, and supporting the development and evaluation of interventions for clinical practice.
trial registrationOSF Registration DOI: https://doi.org/10.17605/OSF.IO/MJAZ3.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.